PANTHERx will dispense KISQALI® (ribociclib) as a first-line treatment for postmenopausal women with an advanced form of breast cancer.
The Food and Drug Administration has approved KISQALI® as a once-daily oral treatment in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Full prescribing information can be found at:
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kisqali.pdf